Concise Review: The Relevance of Human Stem Cell-Derived Organoid Models for Epithelial Translational Medicine§

Authors

  • Robert E. Hynds,

    1. Lungs for Living Research Centre, Division of Medicine, University College London, London, United Kingdom
    Search for more papers by this author
  • Adam Giangreco

    Corresponding author
    1. Lungs for Living Research Centre, Division of Medicine, University College London, London, United Kingdom
    • Lungs for Living Research Centre, Division of Medicine, University College London, Rayne Building, 5 University Street, London, WC1E 6JF, U.K.

    Search for more papers by this author
    • Telephone: 0044 (20)7679 6926; Fax: 0044 (20)7679 6973


  • Author contributions: R.E.H. and A.G.: wrote, edited, and drafted all figures.

  • Disclosure of potential conflicts of interest is found at the end of this article.

  • §

    First published online in STEM CELLSEXPRESS December 3, 2012.

Abstract

Epithelial organ remodeling is a major contributing factor to worldwide death and disease, costing healthcare systems billions of dollars every year. Despite this, most fundamental epithelial organ research fails to produce new therapies and mortality rates for epithelial organ diseases remain unacceptably high. In large part, this failure in translating basic epithelial research into clinical therapy is due to a lack of relevance in existing preclinical models. To correct this, new models are required that improve preclinical target identification, pharmacological lead validation, and compound optimization. In this review, we discuss the relevance of human stem cell-derived, three-dimensional organoid models for addressing each of these challenges. We highlight the advantages of stem cell-derived organoid models over existing culture systems, discuss recent advances in epithelial tissue-specific organoids, and present a paradigm for using organoid models in human translational medicine. STEM CELLS2013;31:417–422

Ancillary